BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Fred E. Cohen sold 54,250 shares of the stock in a transaction on Monday, September 18th. The shares were sold at an average price of $5.42, for a total value of $294,035.00. Following the completion of the sale, the director now owns 173,660 shares in the company, valued at $941,237.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

BioCryst Pharmaceuticals, Inc. (BCRX) opened at 5.24 on Friday. BioCryst Pharmaceuticals, Inc. has a one year low of $3.75 and a one year high of $9.25. The stock’s market cap is $421.44 million. The firm’s 50 day moving average price is $4.87 and its 200 day moving average price is $6.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The firm had revenue of $3.10 million during the quarter, compared to analyst estimates of $5.79 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. The business’s quarterly revenue was down 35.4% compared to the same quarter last year. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post ($0.75) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/23/insider-selling-biocryst-pharmaceuticals-inc-bcrx-director-sells-294035-00-in-stock.html.

BCRX has been the topic of several analyst reports. Piper Jaffray Companies reiterated an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 5th. Noble Financial reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 8th. ValuEngine upgraded BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. Zacks Investment Research cut BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $8.78.

A number of hedge funds have recently modified their holdings of BCRX. Teachers Advisors LLC lifted its holdings in BioCryst Pharmaceuticals by 18.5% in the 4th quarter. Teachers Advisors LLC now owns 125,777 shares of the biotechnology company’s stock worth $796,000 after buying an additional 19,615 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of BioCryst Pharmaceuticals by 206.4% in the 1st quarter. Russell Investments Group Ltd. now owns 49,638 shares of the biotechnology company’s stock valued at $417,000 after purchasing an additional 33,438 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of BioCryst Pharmaceuticals by 6.8% in the 1st quarter. Bank of New York Mellon Corp now owns 361,289 shares of the biotechnology company’s stock valued at $3,035,000 after purchasing an additional 23,072 shares in the last quarter. Swiss National Bank raised its stake in shares of BioCryst Pharmaceuticals by 18.7% in the 1st quarter. Swiss National Bank now owns 114,300 shares of the biotechnology company’s stock valued at $960,000 after purchasing an additional 18,000 shares in the last quarter. Finally, UBS Asset Management Americas Inc. acquired a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at about $392,000. Hedge funds and other institutional investors own 85.80% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.